Browse News
Filter News
Found 1,753 articles
-
Autoimmune Hepatitis Diagnosis and Treatment Market Size Set to Soar USD 19.15 Billion by 2032
4/23/2024
The global autoimmune hepatitis diagnosis and treatment market size is projected to increase from USD 14.03 billion in 2023 to approximately USD 19.15 billion by 2032. This growth, at a CAGR of 3.3% from 2023 to 2032
-
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
4/4/2024
Co-Diagnostics, Inc. today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO).
-
One-on-One, Surgeon-to-Surgeon Bunionplasty® Procedure Training Program Sets New Industry Standard for Minimally Invasive Bunion Surgery Adoption
3/27/2024
Voom™ Medical Devices, Inc. ("Voom"), a revolutionary medical device company transforming the landscape of minimally invasive bunion surgery (MIBS) education, is thrilled to announce the official launch of its new one-on-one surgeon training program for the Bunionplasty® 360 Bunion Repair™ procedure.
-
Liver-Assessment Tool Hepatoscope® Cleared for Use in U.S. and Europe Just as First Medication for MASH* Gains FDA Approval
3/26/2024
E-Scopics, the France-based medical ultrasound company and creator of a unique software-based liver assessment tool, welcomed the announcement that Madrigal Pharmaceuticals’ Rezdiffra™ (resmetirom) has been approved by the U.S. Food and Drug Administration (FDA) to treat certain forms of liver disease.
-
Toyoda Gosei Invests in Yuurea, Inc., a Startup Developing Urine Test Kits for Easy Checks of Physical Condition
3/25/2024
Toyoda Gosei Co., Ltd., as one part of its efforts to develop new businesses that will help to resolve societal challenges in the healthcare field, has invested* in Yuurea, Inc., a company that develops test kits which will allow people to monitor their physical condition simply, using urine samples.
-
The Multiple Sclerosis Association of America (MSAA) Selects SEQSTER to Accelerate Patient-Centricity & Innovation
3/21/2024
SEQSTER PDM Inc., the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America for its patient-centricity, 1-Click Records™ and cutting-edge longitudinal health record.
-
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
3/14/2024
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023.
-
Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
3/8/2024
Senseonics Holdings, Inc. Announces Data From the Eversense ® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes.
-
KARL STORZ Launches CollaboratOR 3D for Apple Vision Pro
3/7/2024
Pioneering MedTech company KARL STORZ is proud to announce the release of the CollaboratOR 3D app for Apple Vision Pro.
-
MEDITECH to Spotlight Intelligent Interoperability at HIMSS24
3/7/2024
MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.
-
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
3/6/2024
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference.
-
FDA Clears First Over-the-Counter Continuous Glucose Monitor
3/5/2024
The U.S. Food and Drug Administration cleared for marketing the first over-the-counter continuous glucose monitor.
-
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
2/29/2024
Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter and full year ended December 31, 2023.
-
UCB on Growth Path for a Decade Plus
2/28/2024
Our 2023 performance showcases our unwavering commitment to ensuring people with severe diseases can live the life they like, as free as possible from challenges of disease, reaching more than 3.2 million patients globally with severe immunological and neurological conditions.
-
Empatica Reveals Next Generation FDA-Cleared Epilepsy Watch and Launches AI Seizure Forecasting Study
2/28/2024
Empatica, a leader in remote health monitoring powered by AI, is proud to announce the official launch of EpiMonitor, the latest advancement in wearable epilepsy monitoring.
-
Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor
2/27/2024
Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM).
-
Phonak Lumity is now available for all ages and hearing loss levels
2/21/2024
Phonak, a global leader in innovative hearing solutions, proudly announces the latest additions to its product lineup: Audéo L-312, Naída L-SP, and Sky L-M and SP.
-
Clearstep Announces Partnership with Tufts Medicine to Enhance Healthcare for Millions of Patients across the New England Region
2/21/2024
Clearstep is excited to announce a notable partnership with Tufts Medicine, a prominent hospital system in Massachusetts, to improve patient access by introducing a virtual care solution to help ensure patients get the right care at the right place and time.
-
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time
2/15/2024
Senseonics Holdings, Inc. announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024.
-
Novel Randomized Control Trial Reveals Impact of Medisafe on Medication Self-Efficacy and Medication Adherence to Improve Health Outcomes in Medically Underserved Populations
2/13/2024
A novel randomized control trial conducted by Vanderbilt University researchers and published in the Journal of Behavioral Medicine explored the effect of smartphone applications on medication adherence in a medically underserved population.